RHHBY

AstraZeneca Plans 2,300 More Job Cuts

AstraZeneca will trim its payroll by another 2,300 jobs, just days after cutting 1,600 other workers, as part of its latest restructuring. More 

FDA Warns Docs as More Fake Cancer Drugs Hit U.S.

The FDA is warning doctors that it has found another counterfeit batch of the cancer-fighting drug Avastin that contains no active ingredients. More 

Biotech Movers: Keryx Jumps, Sarepta Slips

Among last week's highlights, Keryx jumps on a solid Phase III trial, Sarepta gets pounded from a fake tweet and Halozyme suffers from analyst downgrades. More 

FDA Approves Avastin for Continued Cancer Treatment

The FDA on Wednesday approved the use of Roche's Avastin drug with new chemotherapy treatments in patients whose cancer did not improve with its first use. More 

Novartis Chairman Steps Down, Shares Jump

Daniel Vasella announced that he is stepping down as chairman of Novartis and will be replaced by Bayer executive Joerg Reinhardt. More 

Flu Season: Where Investors Can Find Relief

This year's flu looks particularly troublesome, but that's good new for the many companies that benefit from flu sufferers' ills. Here's a look at some of them. More 

Biotech Movers: A Tough Week All Around

Amarin Corp. slides on dashed buyout hopes, while Sarepta, Galena and others also faced serious setbacks. More